Celularity Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Celularity Inc. (CELU) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$19.27 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-04-30
- Celularity Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$19.27M.
- Celularity Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$12.16M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$19.27M 10-K · filed 2026-04-30 |
| 2024-12-31 | -$12.16M 10-K · filed 2026-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |